Pfizer (NYSE:PFE) Shares Up 0.6% – What’s Next?

by · The Cerbat Gem

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price shot up 0.6% during mid-day trading on Monday . The stock traded as high as $25.25 and last traded at $24.95. 12,913,725 shares traded hands during trading, a decline of 66% from the average session volume of 38,117,711 shares. The stock had previously closed at $24.80.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on PFE shares. Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Barclays lifted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $32.92.

View Our Latest Research Report on Pfizer

Pfizer Stock Up 1.0 %

The stock has a 50 day moving average of $28.45 and a 200-day moving average of $28.63. The firm has a market capitalization of $142.24 billion, a P/E ratio of 33.92, a PEG ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the previous year, the business posted ($0.17) EPS. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. Research analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.69%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Olistico Wealth LLC purchased a new position in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer in the second quarter worth approximately $29,000. Gladius Capital Management LP boosted its stake in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP purchased a new stake in Pfizer in the second quarter worth approximately $31,000. Finally, Financial Connections Group Inc. purchased a new stake in Pfizer in the second quarter worth approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Recommended Stories